Search
Sutro Biopharma Inc
STROAdd to Watchlist
15.710USD
-0.020-0.13%
Close 09-24 16:00（ET）
260.31MMarket Cap
LossP/E TTM
Sutro Biopharma Inc (STRO) Stock Price Target & Forecast
Analyst Rating
Based on 14 analysts giving stock ratings to Sutro Biopharma Inc in the past month.
Buy
4 Strong Buy
9 Buy
0 Hold
1 Sell
0 Strong Sell
Target Price
47.231USD+200.26%
STRO Analyst Recommendation Trends
In the current month, STRO has received 9 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. STRO average Analyst price target in the last month is 47.231.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
3
3
2
1
1
1
9
9
9
10
8
7
5
5
0
0
0
0
1
1
3
3
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
14
14
13
14
12
10
10
10
STRO Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, STRO EPS is projected to reach -1.911 in FY2026Q3, following reported EPS of -2.325 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-4.34
-3.77
-2.19
-1.91
-1.79
Actual
-5.35
-2.94
-2.33
--
--
Surprise
-23.26%
+21.99%
-5.99%
--
--
FAQs
What is Sutro Biopharma Inc's expected revenue for the next quarter?
Sutro Biopharma Inc's expected revenue is 10.34M.
What is Sutro Biopharma Inc's price target?
Analysts forecast that Sutro Biopharma Inc's price target is USD 47.23, with the highest forecast at USD 61.00 and the lowest forecast at USD 10.00.
How have Sutro Biopharma IncSTRO's recent earnings per share performed?
The market expectation was USD -2.33, while Sutro Biopharma IncSTRO's earnings per share (EPS) for the previous quarter was USD -2.94. EPS for the next quarter is expected at USD -1.91.
What is the analyst rating for Sutro Biopharma Inc?
Based on the ratings of Sutro Biopharma Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.